Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jianer Qingjie Granules for Pediatric Acute Upper Respiratory Infection (Wind-Heat with Stagnation Pattern)
CTR20233840Phase 2Active
- Sponsor
- China State Institute of Pharmaceutical Industry
- Start
- Dec 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Jianer Qingjie Granules in upper respiratory infection (URI) (3 cohorts), sponsored by China State Institute of Pharmaceutical Industry. Primary endpoints: Clinical cure rate at Day 3 and Traditional Chinese medicine syndrome score and cure rate at Day 3. Started Dec 2023; status: active.
02
Drugs
Jianer Qingjie Granules
03
Conditions
upper respiratory infection (URI)
Beyond the preview
Go deeper on CTR20233840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233840.